Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) EPS (Basic): 2010-2025

Historic EPS (Basic) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Sep 2025 value amounting to $1.19.

  • Ani Pharmaceuticals' EPS (Basic) rose 193.70% to $1.19 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.71, marking a year-over-year increase of 410.91%. This contributed to the annual value of -$1.04 for FY2024, which is 220.93% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' EPS (Basic) is $1.19, which was up 221.62% from $0.37 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' EPS (Basic) ranged from a high of $1.19 in Q3 2025 and a low of -$1.87 during Q4 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median EPS (Basic) value was $0.30 (recorded in 2023), while the average stood at $0.18.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 12,800.00% in 2022, then skyrocketed by 1,300.00% in 2024.
  • Ani Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$1.87 in 2021, then skyrocketed by 84.49% to -$0.29 in 2022, then skyrocketed by 106.90% to $0.02 in 2023, then plummeted by 2,850.00% to -$0.55 in 2024, then soared by 193.70% to $1.19 in 2025.
  • Its last three reported values are $1.19 in Q3 2025, $0.37 for Q2 2025, and $0.70 during Q1 2025.